171 related articles for article (PubMed ID: 23315516)
1. How long has NICE taken to produce Technology Appraisal guidance? A retrospective study to estimate predictors of time to guidance.
Casson SG; Ruiz FJ; Miners A
BMJ Open; 2013 Jan; 3(1):. PubMed ID: 23315516
[TBL] [Abstract][Full Text] [Related]
2. Single technology appraisals by NICE: are they delivering faster guidance to the NHS?
Barham L
Pharmacoeconomics; 2008; 26(12):1037-43. PubMed ID: 19014204
[TBL] [Abstract][Full Text] [Related]
3. NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium.
Ford JA; Waugh N; Sharma P; Sculpher M; Walker A
BMJ Open; 2012; 2(1):e000671. PubMed ID: 22290398
[TBL] [Abstract][Full Text] [Related]
4. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
Kaltenthaler E; Papaioannou D; Boland A; Dickson R
Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
[TBL] [Abstract][Full Text] [Related]
5. A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process.
Walton MJ; O'Connor J; Carroll C; Claxton L; Hodgson R
Pharmacoecon Open; 2019 Sep; 3(3):403-410. PubMed ID: 30617953
[TBL] [Abstract][Full Text] [Related]
6. Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.
Rose M; Rice S; Craig D
Pharmacoecon Open; 2018 Jun; 2(2):97-107. PubMed ID: 29623616
[TBL] [Abstract][Full Text] [Related]
7. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
8. Appraisal of Novel Oncological Therapies by the Scottish Medicines Consortium and the National Institute for Health and Care Excellence: A Comparative Study of Six Years of Data.
Taylor R
Cureus; 2023 Dec; 15(12):e50560. PubMed ID: 38222244
[TBL] [Abstract][Full Text] [Related]
9. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the influence of the publication of the UK National Institute for health and Care Excellence's guidance on hypertension in pregnancy: a retrospective analysis of clinical practice.
Farrar D; Tuffnell D; Sheldon TA
BMC Pregnancy Childbirth; 2020 Feb; 20(1):101. PubMed ID: 32050920
[TBL] [Abstract][Full Text] [Related]
11. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
[TBL] [Abstract][Full Text] [Related]
12. Medicine characteristics affecting the time to guidance publication by National Institute for Health and Care Excellence in the single technology appraisal process.
Takada S; Narukawa M
Int J Technol Assess Health Care; 2021 Dec; 38(1):e11. PubMed ID: 34933699
[TBL] [Abstract][Full Text] [Related]
13. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
[TBL] [Abstract][Full Text] [Related]
14. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
[TBL] [Abstract][Full Text] [Related]
15. Assessment of quality of data submitted for NICE technology appraisals over two decades.
Osipenko L; Ul-Hasan SA; Winberg D; Prudyus K; Kousta M; Rizoglou A; Rustignoli I; van der Maas L
BMJ Open; 2024 Feb; 14(2):e074341. PubMed ID: 38351112
[TBL] [Abstract][Full Text] [Related]
16. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the impact of NICE guidance on GP prescribing.
Wathen B; Dean T
Br J Gen Pract; 2004 Feb; 54(499):103-7. PubMed ID: 14965388
[TBL] [Abstract][Full Text] [Related]
18. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
19. Cross-sectional analysis of use of real-world data in single technology appraisals of oncological medicine by the National Institute for Health and Care Excellence in 2011-2021.
Kang J; Cairns J
BMJ Open; 2024 Mar; 14(3):e077297. PubMed ID: 38485485
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
